Sodyum Selenat – apk haber

Demans Alzheimer'ın Soyut Kavramı

Monash Üniversitesi araştırmacıları, 60’ların altındaki yaygın bir bunama türü için potansiyel yeni bir tedavi buldular. Bir Faz 1 denemesinde sodyum selenat davranışsal sorunları stabilize ettiği ve beyin büzülmesini yavaşlattığı gösterildi ve davranışsal varyant frontotemporal demansı olan hastalar için umut verdi.

Sodyum selenat, 60 yaşın altındakilerde en yaygın ikinci bunama olan davranışsal varyant frontotemporal demansı yavaşlatır.

Monash Üniversitesi liderliğindeki bir çalışma, 60’ların altındaki ikinci en yaygın bunama türü olan davranışsal varyant frontotemporal demansı olan hastalar için umut verici yeni bir tedavi buldu – bu, normalde tırmanan davranış sorunlarının dengelenmesine ve beynin yavaşlamasına neden oldu. hastalık nedeniyle küçülme. Bu, sodyum selenat adlı ilacın bilişsel gerilemeyi ve birçok demansın ayırt edici özelliği olan nörodejeneratif hasarı yavaşlattığını gösteren ikinci klinik çalışmadır.[{” attribute=””>Alzheimer’s Disease.

Behavioral variant frontotemporal dementia (bvFTD) is a rapidly progressing destructive disease and can occur in people as young as 35 years of age. It is characterized by behavioral disturbances and personality changes and can be highly disruptive and distressing for both patients and their families. Currently, there are no treatments or cures for bvFTD and typical survival is 5-7 years from diagnosis. 

The Phase 1 trial run in conjunction with the Royal Melbourne Hospital, the only one in Australia targeting non-genetic bvFTD, and one of a handful worldwide, showed that the drug, sodium selenate is safe and well-tolerated in patients with bvFTD over a period of 12 months.  Importantly, the majority of patients receiving sodium selenate showed no change in their cognitive or behavioral symptoms, and reduced rates of brain atrophy over the trial period. The results from the trial, led by Dr. Lucy Vivash, from Monash University’s Department of Neuroscience, have just been published in the journal, Alzheimer’s and Dementia: Translational Research and Clinical Interventions

In almost half of the cases with bvFTD, the damage to the neurons in the brain is caused by the build-up of a protein called tau. This protein is a major target for research in the prevention and treatment of Alzheimer’s and other dementias, as a way to reverse the neurodegeneration caused by this tau accumulation.

According to Dr. Vivash, sodium selenate upregulates an enzyme in the brain that effectively breaks down the tau protein. “We have previously shown, in a Phase 2 trial, that sodium selenate given to patients with mild to moderate Alzheimer’s Disease resulted in less neurodegeneration than in those who did not,” she said. Importantly those patients in the trial with higher levels of selenium, a breakdown product of sodium selenate, in their bloodstream showed less cognitive decline.

Reference: “A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia” by Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao-Xin Li, Stuart McDonald, William T. O’Brien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis and Terence J. O’Brien, 5 May 2022, Alzheimer s & Dementia Translational Research & Clinical Interventions.
DOI: 10.1002/trc2.12299

The research group is now conducting a larger study at many hospitals across Australia and New Zealand to further test whether this drug is beneficial for patients with bvFTD. For more information please contact [email protected]

Yorum yapın